Volvo delivers a unique combination of performance and efficiency with the High Performance Drive-E Powertrain Concept - a triple boost 2-liter 4-cylinder petrol engine with no less than 450 hp.
Following the successful introduction of Volvo’s Drive-E Powertrain range in 2013, Volvo’s powertrain team once again demonstrates its technological leadership in emission-reducing turbo technology.
“When we launched the Drive-E powertrain family, our aim was to deliver the most advanced 4-cylinder engines in the industry based on emissions and fuel consumption relative to performance and drivability. We knew that 320 hp in our petrol configuration was just a starting point. The 450 hp High Performance Drive-E Powertrain Concept, demonstrates this ambition and the versatility of the Drive-E Powertrains,” says Dr. Peter Mertens, Senior Vice President for Research and Development at Volvo Car Group.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762550-volvo-reveal-drive-e-450hp-engine/
1. Offer available from December 25 2014 for a limited time only in Sydney and participating regions.
2. Orders already confirmed cannot avail of the offer. It is only open to new inquiries from 25/12/2014. Quotes prior to the sale can be requoted upon request to take up the offer.
3. Not valid with any other discounts or interest free offer.
4. Installation and accessories do not form part of the offer and will be charged as per the normal retail prices.
5. Discount is off Apollo’s normal selling prices.
6. The ranges applicable are as follows:
*20% Off
Panel Glides
Cellular Blinds
Viewline Shades
* 25% Off
Roller Blinds
Fabric Verticals
Venetians
Roller Shutters
Roman Blinds
* 30% Off
Awnings
* 35% Off
Shicane Verticals
*40% Off
All Louvre Shutters
http://apolloblinds.com.au/specials-2/
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
ACG – the leading partner for pharmaceutical industry’s myriad requirements – is strengthening its product portfolio by launching several new machines at CPhI/P-MEC India, to be held during 2-4 December 2014, at Bombay Exhibition Centre, Mumbai.
P-MEC India, co-located with CPhI India, is one of the ‘must-attend’ events in the international pharmaceutical industry. With a booth that spreads over 1,000 sq. m., ACG will be displaying several new machines including the all-new ACG X.One Technology that reinvents the 12-bar safety features; Protab, a tablet press suited for small to medium batch sizes, and many more.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7391551-ACG-Launch-New-Machines-at-CPhI/
Topics covered by Shaikh Ahmed Moait:
1. Building habits inside the house
2. Mutual agreement between the spouses
3. Youth!! please listen before the damage is done
4. children show their love by imitating you
5. Cleanliness
6. We are all just a bunch of habits
7. Do you eat according to principle or habits
8. I have to be a role model!!
